Table 2.
Baseline characteristics of patients, by biomarker result and data curation approach.
| ROS1-Positive | ROS1-Negative | |||||
|---|---|---|---|---|---|---|
| Abstracted Cohort | ML-Extracted Cohort | aSMD | Abstracted Cohort | ML-Extracted Cohort | aSMD | |
| N | 349 | 367 | 27,478 | 29,219 | ||
| Practice Type, n (%) | 0.02 | 0.01 | ||||
| Academic | 94 (26.9%) | 102 (27.8%) | 3907 (14.2%) | 4032 (13.8%) | ||
| Community | 255 (73.1%) | 265 (72.2%) | 23,571 (85.8%) | 25,187 (86.2%) | ||
| Gender, n (%) | 0.06 | 0.00 | ||||
| Female | 217 (62.2%) | 218 (59.4%) | 12,966 (47.2%) | 13,790 (47.2%) | ||
| Male | 132 (37.8%) | 149 (40.6%) | 14,510 (52.8%) | 15,427 (52.8%) | ||
| Race/ethnicity, n (%) | 0.03 | 0.01 | ||||
| Black or African American | 38 (10.9%) | 42 (11.4%) | 2419 (8.8%) | 2568 (8.8%) | ||
| Other race a | 64 (18.3%) | 70 (19.1%) | 3637 (13.2%) | 3901 (13.4%) | ||
| Unknown | 32 (9.2%) | 35 (9.5%) | 2794 (10.2%) | 3009 (10.3%) | ||
| White | 215 (61.6%) | 220 (59.9%) | 18,628 (67.8%) | 19,741 (67.6%) | ||
| Age at advanced diagnosis, median [IQR] | 65 (55, 75) | 65 (54, 74) | 0.02 | 69 (62, 76) | 69 (62, 76) | 0.00 |
| Advanced diagnosis year, n (%) | 0.16 | 0.04 | ||||
| 2011 | 3 (0.9%) | 4 (1.1%) | 95 (0.3%) | 105 (0.4%) | ||
| 2012 | 10 (2.9%) | 7 (1.9%) | 253 (0.9%) | 272 (0.9%) | ||
| 2013 | 12 (3.4%) | 16 (4.4%) | 638 (2.3%) | 676 (2.3%) | ||
| 2014 | 18 (5.2%) | 18 (4.9%) | 1147 (4.2%) | 1229 (4.2%) | ||
| 2015 | 15 (4.3%) | 14 (3.8%) | 2025 (7.4%) | 2091 (7.2%) | ||
| 2016 | 37 (10.6%) | 34 (9.3%) | 2647 (9.6%) | 2791 (9.6%) | ||
| 2017 | 56 (16.0%) | 52 (14.2%) | 3487 (12.7%) | 3719 (12.7%) | ||
| 2018 | 44 (12.6%) | 46 (12.5%) | 3726 (13.6%) | 3949 (13.5%) | ||
| 2019 | 47 (13.5%) | 44 (12.0%) | 3811 (13.9%) | 3997 (13.7%) | ||
| 2020 | 36 (10.3%) | 49 (13.4%) | 3713 (13.5%) | 3812 (13.0%) | ||
| 2021 | 49 (14.0%) | 53 (14.4%) | 3708 (13.5%) | 3917 (13.4%) | ||
| 2022 | 22 (6.3%) | 30 (8.2%) | 2228 (8.1%) | 2661 (9.1%) | ||
| Group stage, n (%) | 0.10 | 0.06 | ||||
| Stage I | 16 (4.6%) | 17 (4.6%) | 2331 (8.5%) | 2582 (8.8%) | ||
| Stage II | 5 (1.4%) | 5 (1.4%) | 1387 (5.0%) | 1438 (4.9%) | ||
| Stage III | 60 (17.2%) | 53 (14.4%) | 5514 (20.1%) | 5832 (20.0%) | ||
| Stage IV | 262 (75.1%) | 288 (78.5%) | 17,692 (64.4%) | 18,999 (65.0%) | ||
| Group stage is not reported | 6 (1.7%) | 4 (1.1%) | 554 (2.0%) | 368 (1.3%) | ||
| Histology, n (%) | 0.08 | 0.04 | ||||
| Non-squamous cell carcinoma | 313 (89.7%) | 334 (91.0%) | 20,266 (73.8%) | 21,880 (74.9%) | ||
| NSCLC histology NOS | 12 (3.4%) | 8 (2.2%) | 1274 (4.6%) | 1155 (4.0%) | ||
| Squamous cell carcinoma | 24 (6.9%) | 25 (6.8%) | 5938 (21.6%) | 6184 (21.2%) | ||
| ECOG PS at advanced diagnosis, n (%) | 0.10 | 0.02 | ||||
| 0 | 86 (24.6%) | 82 (22.3%) | 5549 (20.2%) | 5985 (20.5%) | ||
| 1 | 99 (28.4%) | 99 (27.0%) | 7762 (28.2%) | 8405 (28.8%) | ||
| 2 | 18 (5.2%) | 17 (4.6%) | 2588 (9.4%) | 2788 (9.5%) | ||
| 3 | 5 (1.4%) | 4 (1.1%) | 618 (2.2%) | 632 (2.2%) | ||
| 4 | 0 (0.0%) | 0 (0.0%) | 32 (0.1%) | 34 (0.1%) | ||
| Missing/not documented | 141 (40.4%) | 165 (45.0%) | 10,929 (39.8%) | 11,375 (38.9%) | ||
| PD-L1 status, n (%) | 0.09 | 0.07 | ||||
| Negative | 57 (16.3%) | 56 (15.3%) | 6548 (23.8%) | 6878 (23.5%) | ||
| Positive | 178 (51.0%) | 189 (51.5%) | 12,500 (45.5%) | 13,162 (45.0%) | ||
| Unknown | 21 (6.0%) | 30 (8.2%) | 1117 (4.1%) | 1614 (5.5%) | ||
| Not tested | 93 (26.6%) | 92 (25.1%) | 7313 (26.6%) | 7565 (25.9%) | ||
| Treatment received, n (%) | 0.13 | 0.03 | ||||
| Non-oral antineoplastic | 51 (14.6%) | 68 (18.5%) | 19,505 (71.0%) | 20,662 (70.7%) | ||
| Other oral therapy | 36 (10.3%) | 33 (9.0%) | 2691 (9.8%) | 2674 (9.2%) | ||
| ROS1 inhibitor | 224 (64.2%) | 220 (59.9%) | 159 (0.6%) | 139 (0.5%) | ||
| No treatment documented | 38 (10.9%) | 46 (12.5%) | 5123 (18.6%) | 5744 (19.7%) | ||
Abbreviations: aSMD: absolute standardized mean difference; ECOG PS: Eastern Cooperative Oncology Group performance status; IQR: interquartile range; NSCLC: non-small cell lung cancer; PD-L1: programmed; death-ligand 1; a Patients who reported Hispanic or Latinx ethnicity, regardless of race, were included in Other race.